A dual-targeting liposome conjugated with transferrin and arginine-glycine-aspartic acid peptide for glioma-targeting therapy
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The treatment of a brain glioma remains one of the most difficult challenges in oncology. In the present study a delivery system was developed for targeted drug delivery across the blood‑brain barrier (BBB) to the brain cancer cells. A cyclic arginine‑glycine‑aspartic acid (RGD) peptide and transferrin (TF) were utilized as targeting ligands. Cyclic RGD peptides are specific targeting ligands of cancer cells and TFs are ligands that specifically target the BBB and cancer cells. Liposome (LP) was used to conjugate the cyclic RGD and TFs to establish the brain glioma cascade delivery system (RGD/TF‑LP). The LPs were prepared by the thin film hydration method and physicochemical characterization was conducted. In vitro cell uptake and three‑dimensional tumor spheroid penetration studies demonstrated that the system could target endothelial and tumor cells, as well as penetrate the tumor cells to reach the core of the tumor spheroids. The results of the in vivo imaging further demonstrated that the RGD/TF‑LP provided the highest brain distribution. As a result, the paclitaxel‑loaded RGD/TF‑LP presents the best antiproliferative activity against C6 cells and tumor spheroids. In conclusion, the RGD/TF‑LP may precisely target brain glioma, which may be valuable for glioma imaging and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Transport of drugs across the blood–brain barrier by nanoparticles.
Wohlfart, S., Gelperina, S., & Kreuter, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.08.017 · Cited by 715 · cited 1×
“Similarly, particle size is an important factor that affects the LP endocytosis by the brain capillary cells on the BBB, and the size distribution is generally limited to ~200 nm in diameter for brain‑targeted LPs (28).”
3D cell culture systems modeling tumor growth determinants in cancer target discovery
Thoma, C. R., Zimmermann, M., Agarkova, I., Kelm, J. M., & Krek, W. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.03.001 · Cited by 478
Cited by
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
Vieira, D., & Gamarra, L. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s117210 · Cited by 427
Lam, F. C., Morton, S. W., Wyckoff, J., Vu Han, T.-L., Hwang, M. K., Maffa, A., Balkanska-Sinclair, E., Yaffe, M. B., Floyd, S. R., & Hammond, P. T. (2018) · Nature Communications · doi:10.1038/s41467-018-04315-4 · Cited by 330
Belfiore, L., Saunders, D. N., Ranson, M., Thurecht, K. J., Storm, G., & Vine, K. L. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.040 · Cited by 294
Advances in liposomal drug delivery to cancer: An overview
Saraf, S., Jain, A., Tiwari, A., Verma, A., Panda, P. K., & Jain, S. K. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101549 · Cited by 237
Engineering liposomal nanoparticles for targeted gene therapy
Zylberberg, C., Gaskill, K., Pasley, S., & Matosevic, S. (2017) · Gene Therapy · doi:10.1038/gt.2017.41 · Cited by 204
Design of liposomal formulations for cell targeting
Nogueira, E., Gomes, A. C., Preto, A., & Cavaco-Paulo, A. (2015) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2015.09.034 · Cited by 173
Nanotheranostics: Emerging Strategies for Early Diagnosis and Therapy of Brain Cancer
Sonali, Viswanadh, M. K., Singh, R. P., Agrawal, P., Mehata, A. K., Pawde, D. M., Narendra, Sonkar, R., & Muthu, M. S. (2018) · Nanotheranostics · doi:10.7150/ntno.21638 · Cited by 169
“In recent years, dual targeting nanomedicines are also reported for brain-targeted diagnosis and therapy [37-39].”
BackgroundTumor Microenvironment Targeted Nanotherapy
Fernandes, C., Suares, D., & Yergeri, M. C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01230 · Cited by 161
“Qin et al. (2014) designed dual cyclic RGD peptide- and transferrin-conjugated PTX-loaded liposomes for targeting the blood-brain-barrier and targeting to brain glioma cell.”
BackgroundLakkadwala, S., dos Santos Rodrigues, B., Sun, C., & Singh, J. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.033 · Cited by 160
Metadata
- Authors
- QIN, L., WANG, C.-Z., FAN, H.-J., ZHANG, C.-J., ZHANG, H.-W., LV, M.-H., & CUI, S.-D.
- Venue
- Oncology Letters
- Publisher
- Spandidos Publications
- Published
- 2014-08-14
- Volume
- 8
- Issue
- 5
- Pages
- 2000-2006
- ISSN
- 1792-1074 (ISSN-L)
- 1792-1082
- OpenAlex
- W2150439931
- Cited by
- 105
- References
- 3
- FWCI
- 2.80
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.